Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Nephrology

Treatment Strategy: Diet and Medications for SHPT

At a Glance

Treatment for secondary hyperparathyroidism of renal origin is tailored to kidney function and lab results. Options include phosphorus-conscious eating, phosphate binders, vitamin D, or calcimimetic medicines, with close monitoring to prevent calcium problems and overly low parathyroid hormone levels.

Treating secondary hyperparathyroidism (SHPT) is highly individualized. Your doctors are trying to keep your calcium, phosphorus (phosphate), and parathyroid hormone in a safe balance to protect your bones and your cardiovascular system [1][2].

Because the risks of treatment change as your kidney function declines, your nephrology team will tailor your medications based on your specific lab trends [3][4]. Never start, stop, or change your medications based on this guide without consulting your doctor.

Diet and Phosphate Control

A foundational part of managing CKD-MBD is managing phosphorus.

  • Dietary Adjustments: Rather than making severe restrictions on your own (which can lead to dangerous malnutrition), ask for a referral to a renal dietitian. They can help you identify high-phosphorus foods while ensuring you still get enough protein and calories.
  • Watch for Additives: Many processed foods and sodas contain inorganic phosphate additives (look for words containing “phos-” on the ingredient label). Your body absorbs these additives very easily, whereas phosphorus naturally found in plant foods is absorbed much less efficiently [3][5].
  • Phosphate Binders: These are medications you take with meals or snacks. They act like a sponge, soaking up phosphorus in your gut before it can enter your bloodstream [6].
    • Calcium-based binders (e.g., calcium acetate/carbonate) are common but can sometimes lead to high blood calcium if overused [6][7].
    • Non-calcium binders (e.g., sevelamer, lanthanum) are often used if your calcium levels are already high or to mitigate vascular calcification risks [8][9].
    • Side effects: Binders can cause gastrointestinal issues like constipation or nausea. Tell your team if you experience this so they can adjust your dose or type.

Vitamin D Therapies

Your body needs Vitamin D to manage calcium, but treatments vary based on your labs and CKD stage.

  • Nutritional Vitamin D: Doctors often start with “native” Vitamin D (like cholecalciferol or ergocalciferol) to correct a simple deficiency and to maintain healthy levels [10][5][11].
  • Active Vitamin D (Analogues): If PTH continues to rise, doctors may prescribe “active” forms like calcitriol [12].
  • The Risk: Active Vitamin D can increase the amount of calcium and phosphorus you absorb from food. In early (non-dialysis) CKD, these are used very cautiously because hypercalcemia (high calcium) can accelerate kidney damage or cause adynamic (low-turnover) bone disease [5][13].

Calcimimetics

If you are on dialysis and your PTH remains high, your doctor may consider a calcimimetic (such as cinacalcet or the intravenous etelcalcetide) [14]. In some advanced cases where medications are no longer effective, a surgical procedure may be needed [15].

  • How they work: These drugs “trick” the parathyroid glands into sensing that there is plenty of calcium in the blood, which suppresses PTH production [16].
  • The Effect: Calcimimetics reliably lower PTH and commonly lower serum calcium. However, they do not replace the need for dietary phosphate management or binders [14].
  • The Side Effects: The most common side effects are nausea and vomiting [17]. Because they can cause your calcium to drop too low (hypocalcemia), your blood levels will be monitored closely [14][18].

A Note on “Overtreatment”

It is possible to suppress PTH too far. If your PTH drops below your target range, your bone cells can stop their healthy cycle of “recycling.” This leads to adynamic bone disease, which increases your risk of fractures and cardiovascular complications [13][19]. Your doctor may reduce your medications if your PTH levels drop too low [20].

Common questions in this guide

What foods and ingredients should I watch when managing renal SHPT?
Phosphorus control is an important part of managing renal secondary hyperparathyroidism. Processed foods and sodas may contain phosphate additives, often identified by words beginning with “phos-” on the label. A renal dietitian can help limit phosphorus while preserving adequate protein and calories, so avoid making severe restrictions on your own.
When should I take a phosphate binder for SHPT?
Phosphate binders are usually taken with the first bites of meals or snacks, exactly as prescribed. Calcium-based and non-calcium binders may be selected for different calcium and cardiovascular considerations. Constipation, nausea, or other stomach problems should be reported so the treatment can be adjusted.
What is the difference between nutritional and active vitamin D for kidney disease?
Nutritional vitamin D, such as cholecalciferol or ergocalciferol, is commonly used to correct a deficiency or maintain healthy levels. Active vitamin D, such as calcitriol, may be considered when parathyroid hormone continues to rise. The choice depends on kidney stage and laboratory results because active vitamin D can raise calcium and phosphorus.
When are calcimimetics used for renal secondary hyperparathyroidism?
For people on dialysis whose parathyroid hormone remains high, a clinician may consider cinacalcet or intravenous etelcalcetide. These medicines lower parathyroid hormone by making the parathyroid glands sense that there is enough calcium in the blood. They can also lower calcium, so blood levels need close monitoring and they do not replace phosphate control or binders.
Can SHPT treatment lower parathyroid hormone too much?
Yes. If parathyroid hormone falls below its target range, adynamic bone disease can develop, slowing the normal bone renewal cycle and increasing fracture and cardiovascular risks. A doctor may reduce or change medication when levels become too low.
When might surgery be needed for renal secondary hyperparathyroidism?
Parathyroidectomy may be considered when advanced renal secondary hyperparathyroidism remains uncontrolled despite medication. The nephrology and surgical teams can review parathyroid hormone, calcium, phosphorus, kidney function, and treatment response to decide whether surgery is appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current CKD stage, should we be focusing on 'nutritional' vitamin D (like cholecalciferol) or do I need an 'active' form like calcitriol?
  2. 2.Is my current phosphate binder calcium-based, and is there any reason I should switch to a non-calcium binder to protect my heart and blood vessels?
  3. 3.If we start a calcimimetic like cinacalcet, how will we monitor for low calcium (hypocalcemia) and what symptoms should I watch for?
  4. 4.What is the long-term plan if my PTH continues to rise despite these medications—is surgery (parathyroidectomy) something I should prepare for?
  5. 5.Can you refer me to a renal dietitian to help me manage my phosphorus intake without losing too much protein?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

    Ketteler M, Block GA, Evenepoel P, et al.

    Annals of internal medicine 2018; (168(6)):422-430 doi:10.7326/M17-2640.

    PMID: 29459980
  2. 2

    Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.

    Waziri B, Duarte R, Naicker S

    International journal of nephrology and renovascular disease 2019; (12()):263-276 doi:10.2147/IJNRD.S191156.

    PMID: 31920363
  3. 3

    Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.

    Bacchetta J, Bernardor J, Garnier C, et al.

    Calcified tissue international 2021; (108(1)):116-127 doi:10.1007/s00223-020-00665-8.

    PMID: 31996964
  4. 4

    Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.

    Ketteler M, Ambühl P

    Journal of nephrology 2021; (34(5)):1405-1418 doi:10.1007/s40620-021-01082-2.

    PMID: 34170509
  5. 5

    Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.

    Ketteler M, Bover J, Mazzaferro S

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(6)):1397-1404 doi:10.1093/ndt/gfac236.

    PMID: 35977397
  6. 6

    Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.

    Sekercioglu N, Angeliki Veroniki A, Thabane L, et al.

    PloS one 2017; (12(3)):e0171028 doi:10.1371/journal.pone.0171028.

    PMID: 28248961
  7. 7

    The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.

    Habbous S, Przech S, Acedillo R, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(1)):111-125 doi:10.1093/ndt/gfw312.

    PMID: 27651467
  8. 8

    Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

    Ruospo M, Palmer SC, Natale P, et al.

    The Cochrane database of systematic reviews 2018; (8()):CD006023 doi:10.1002/14651858.CD006023.pub3.

    PMID: 30132304
  9. 9

    Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.

    Ogata H, Fukagawa M, Hirakata H, et al.

    JAMA 2021; (325(19)):1946-1954 doi:10.1001/jama.2021.4807.

    PMID: 34003226
  10. 10

    Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis.

    Bover J, Gunnarsson J, Csomor P, et al.

    Clinical kidney journal 2021; (14(10)):2177-2186 doi:10.1093/ckj/sfab035.

    PMID: 34603696
  11. 11

    Vitamin D and Vitamin D Analogues in Hemodialysis Patients: A Review of the Literature.

    Kantartzi K, Roumeliotis S, Polychronidis C, et al.

    International journal of molecular sciences 2025; (26(23)) doi:10.3390/ijms262311550.

    PMID: 41373702
  12. 12

    Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients.

    Murt A

    World journal of nephrology 2025; (14(4)):110817 doi:10.5527/wjn.v14.i4.110817.

    PMID: 41479833
  13. 13

    Pleiotropic effects of vitamin D in chronic kidney disease.

    Liu WC, Wu CC, Hung YM, et al.

    Clinica chimica acta; international journal of clinical chemistry 2016; (453()):1-12.

    PMID: 26656443
  14. 14

    Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.

    Nakai K, Kono K, Yamada S, et al.

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024; (28(4)):557-571 doi:10.1111/1744-9987.14125.

    PMID: 38499495
  15. 15

    Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

    Lau WL, Obi Y, Kalantar-Zadeh K

    Clinical journal of the American Society of Nephrology : CJASN 2018; (13(6)):952-961 doi:10.2215/CJN.10390917.

    PMID: 29523679
  16. 16

    Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.

    Pereira L, Meng C, Marques D, Frazão JM

    Clinical kidney journal 2018; (11(1)):80-88 doi:10.1093/ckj/sfx125.

    PMID: 29423207
  17. 17

    Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.

    Xu J, Yang Y, Ma L, et al.

    International urology and nephrology 2019; (51(11)):2027-2036 doi:10.1007/s11255-019-02271-6.

    PMID: 31531805
  18. 18

    The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.

    Bucharles SGE, Barreto FC, Riella MC

    Jornal brasileiro de nefrologia 2019; (41(3)):336-344 doi:10.1590/2175-8239-JBN-2018-0219.

    PMID: 31419274
  19. 19

    Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.

    Fusaro M, Pereira L, Bover J

    Journal of clinical medicine 2023; (12(19)) doi:10.3390/jcm12196306.

    PMID: 37834950
  20. 20

    We Use Too Much Vitamin D in Hemodialysis Patients.

    Reilly RF

    Seminars in dialysis 2016; (29(4)):320-2 doi:10.1111/sdi.12499.

    PMID: 27075415

This page explains diet and medication options for secondary hyperparathyroidism of renal origin for informational purposes only and does not constitute medical advice. Do not change phosphate binders, vitamin D, or other treatment without your nephrology team.

Get notified when new evidence is published on secondary hyperparathyroidism of renal origin.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.